Our Lipids-Oligonucleotide Conjugation services support pharmaceutical researchers, biotechnology companies, delivery platform teams, and academic laboratories that need custom hydrophobe-modified oligonucleotides for uptake studies, membrane interaction research, self-assembly, and delivery-focused development. Lipid-oligonucleotide conjugates can be configured for siRNA, antisense oligonucleotides, DNA, RNA, aptamers, and related synthetic nucleic acid formats using cholesterol, tocopherol, stearyl, fatty acid, phospholipid, and PEG-lipid designs. Because lipid installation changes hydrophobicity, purification behavior, and downstream assay performance, each program requires careful control of lipid class, attachment site, linker architecture, and analytical release strategy.
Our platform integrates conjugate design, functional-handle planning, custom oligonucleotide synthesis or client-material intake, lipid coupling, purification, and analytical characterization to help teams move efficiently from concept to usable research material. By combining nucleic acid chemistry expertise with delivery-aware project planning, we provide fit-for-purpose support for discovery, assay development, and nonclinical evaluation while keeping a strong focus on structural integrity, batch reproducibility, and practical data handoff.
Attachment Site and Activity Control: A lipid can improve membrane interaction, but the wrong placement can reduce hybridization, duplex loading, or target recognition. We evaluate 3', 5', and handle-directed internal attachment strategies to balance conjugation efficiency with oligonucleotide function.
Hydrophobicity and Solubility Balance: As lipid loading increases, oligonucleotides often become harder to dissolve, transfer, and purify. We support spacer selection, sequence-aware design review, and handling strategy planning to reduce aggregation and improve formulation practicality.
Purification and Product Heterogeneity: Lipid installation can generate unreacted starting material, partially modified species, and isomer-related complexity. Our workflows are designed to match conjugation chemistry with appropriate purification logic and analytical confirmation before project release.
Modality and Delivery Fit: siRNA, ASO, DNA, and RNA programs do not respond to lipid conjugation in the same way. We align conjugate architecture with oligonucleotide type, duplex or single-strand format, and downstream use case, including compatibility with broader drug delivery platform strategies.
Analytical Confidence: Lipid-oligonucleotide conjugates require more than a simple sequence check. We combine identity, purity, and conjugation verification with project-specific review of linker integrity, hydrophobe incorporation, and material readiness for research use.
Our service platform is designed for organizations that need technically coordinated support across oligonucleotide design, lipid installation, purification, and characterization rather than a simple modification step in isolation. We support projects involving delivery-oriented siRNA and ASO constructs, membrane-anchored probes, self-assembling nucleic acid systems, and custom hydrophobe-labeled oligonucleotides for formulation and assay research.
By integrating nucleic acid chemistry, linker planning, conjugation execution, and release analytics, we help reduce rework caused by poorly matched lipid choices, unstable coupling designs, or inadequate purification strategies.
The table below summarizes common lipid conjugate formats and the design factors that typically influence service selection, construct planning, and downstream workflow fit.
| Conjugate Format | Typical Design Goal | Common Attachment Options | Key Advantages | Main Watchpoints | Typical Research Fit |
| Cholesterol / Sterol Conjugate | Increase hydrophobic character and support membrane interaction or exposure-oriented construct design | 3' or 5' terminal attachment with spacer-controlled orientation | Broad familiarity, strong lipophilic character, useful for screening multiple construct hypotheses | Can alter duplex behavior, solubility, and purification profile if poorly positioned | siRNA, ASO, membrane-association studies, delivery-focused comparison panels |
| Tocopherol Conjugate | Add a lipophilic vitamin-derived moiety for uptake and distribution-oriented studies | Terminal attachment with flexible linker or spacer design | Strong hydrophobe option with distinct physicochemical behavior relative to sterols | Handling and purification may become more demanding with short or highly hydrophobic constructs | Single-stranded oligos, duplex screening, comparative lipid evaluation programs |
| Stearyl / Long-Chain Alkyl | Promote membrane anchoring, amphiphilic behavior, or self-assembly potential | Usually terminal installation through defined linker chemistry | Straightforward hydrophobic tail design and compatibility with multiple research concepts | High retention during purification and greater aggregation risk in some sequence contexts | Membrane probes, assembly studies, delivery and uptake feasibility work |
| Fatty Acid Conjugate | Tune hydrophobicity with chain-specific lipid motifs | Terminal or handle-directed installation depending on construct design | Flexible lipid class selection and useful for structure-property comparisons | Chain-dependent effects on solubility, stability, and chromatographic behavior | Exposure studies, custom screening libraries, self-assembling oligonucleotide systems |
| PEG-Lipid Hybrid | Balance hydrophobicity with improved handling and spacing | Lipid-spacer-oligonucleotide architectures with configurable PEG length | Better control over steric spacing and often more manageable solution behavior | Larger linker architectures can complicate synthesis design and analytical interpretation | Delivery research, formulation-oriented constructs, multifunctional conjugate design |
| Phospholipid / Custom Client Lipid | Build project-specific hydrophobic constructs for specialized platforms | Case-dependent attachment via preinstalled handle or client-defined chemistry | High design flexibility for differentiated programs and proprietary concepts | Requires compatibility review for handle stability, purity, and purification feasibility | Custom platform development, formulation studies, proprietary delivery research |
Successful lipid-oligonucleotide programs depend on early review of sequence format, attachment site, linker design, hydrophobicity burden, and release analytics. The matrix below shows the main development categories used to de-risk construct progression and match chemistry choices with research-stage objectives.
| Development Category | Objective | Typical Considerations | Applicable Programs | Expected Output |
| Oligonucleotide Format Review | Confirm whether the sequence is best handled as siRNA, ASO, DNA, RNA, or another custom scaffold | Strand structure, backbone modifications, duplex requirements, end-group availability | All lipid-conjugated oligonucleotide projects | Fit-for-purpose design direction |
| Attachment Site Assessment | Select a conjugation position that preserves functional performance | 3'/5' placement, internal handle feasibility, steric impact near active regions | siRNA, ASO, probes, membrane-anchored constructs | Defined site-of-attachment plan |
| Linker and Spacer Planning | Balance flexibility, separation, and structural stability | TEG, PEG, alkyl spacers, cleavable versus stable linkers, linker length | Cholesterol, tocopherol, fatty acid, PEG-lipid constructs | Recommended linker architecture |
| Hydrophobicity Risk Review | Anticipate handling and solubility problems before synthesis and purification | Sequence composition, number of lipids, spacer design, buffer compatibility | Highly lipophilic and multifunctional conjugates | Handling and dissolution guidance |
| Conjugation Route Selection | Match chemistry strategy with construct complexity and material source | Presynthetic incorporation, postsynthetic coupling, client-supplied lipid compatibility | Standard and custom conjugation programs | Executable chemistry workflow |
| Purification Strategy Design | Remove unconjugated and partially modified species efficiently | RP-HPLC or other fit-for-purpose methods, retention behavior, impurity profile | All hydrophobic oligonucleotide conjugates | Purification and recovery plan |
| Analytical Characterization | Confirm identity, purity, and conjugation integrity before release | LC-MS, HPLC, UV profile, composition review, lot documentation | Discovery and nonclinical material supply | Release-ready analytical package |
| Delivery Context Review | Align construct choice with the intended uptake or formulation study | Direct conjugate use, liposome or LNP compatibility, membrane interaction goals | Delivery-focused research and assay development | Practical downstream use guidance |
This workflow reflects how research teams typically engage us for custom lipid-oligonucleotide development, from early construct planning through chemistry execution, analytical confirmation, and technical handoff.
We confirm oligonucleotide type, intended research use, preferred lipid class, target scale, and expected deliverables. This stage establishes whether the project centers on siRNA, ASO, DNA, RNA, probe, or custom construct development.
Our team reviews attachment position, linker requirements, hydrophobicity risk, and the compatibility of client-supplied or platform lipids with the selected oligonucleotide chemistry. A fit-for-purpose conjugation and analytical plan is then defined.
We prepare the required oligonucleotide substrate through custom synthesis or accepted starting material intake, including any terminal or internal handles needed for downstream lipid attachment. Sequence architecture and release targets are finalized before coupling.
The selected lipid conjugation chemistry is executed under conditions appropriate for the construct and linker design. The resulting material is then purified using methods suitable for hydrophobic conjugates and impurity removal.
Identity, purity, and conjugation integrity are assessed using agreed analytical methods such as LC-MS and HPLC. Data are reviewed against project expectations to confirm that the material is appropriate for the intended research workflow.
We provide the agreed documentation package, including construct summary, analytical results, and handling guidance where applicable. For delivery-oriented projects, we can also support transition into formulation or biological evaluation planning.
Lipid-oligonucleotide projects often fail when chemistry design, purification planning, and downstream use are treated as separate tasks. Our service model is built to connect these steps so clients receive constructs that are not only chemically correct, but also more practical for real research workflows.
Lipid-oligonucleotide conjugates are used in a wide range of research and platform-development settings where direct hydrophobe installation can influence uptake behavior, membrane interaction, self-assembly, or formulation compatibility. Our services support customers who need custom constructs matched to specific experimental questions rather than generic labeled oligonucleotides.
Whether you need a cholesterol-conjugated oligonucleotide, a tocopherol-labeled siRNA, a stearyl-modified probe, a PEG-lipid construct, or a broader custom lipid-oligonucleotide development workflow, our team can help you translate project goals into workable chemistry and release-ready material. We support biotech companies, pharmaceutical R&D teams, delivery platform developers, and academic research groups with practical guidance on attachment strategy, lipid selection, purification, and analytical characterization. From early feasibility review through conjugation execution and technical handoff, our services are structured to reduce avoidable risk and improve research readiness for complex hydrophobic oligonucleotide constructs. Contact us to discuss your lipid-oligonucleotide conjugation requirements.
Lipids-oligonucleotide conjugation (LOC) involves chemically linking lipids (such as phospholipids, fatty acids, or cholesterol) to oligonucleotides (such as DNA or RNA). This creates stable conjugates that have applications in targeted delivery and controlled release, making them valuable in gene therapy, vaccine research, and drug delivery.
LOCs are widely used in gene therapy, vaccine research, and targeted drug delivery. They enable efficient gene delivery, enhance vaccine efficacy by targeting specific cells, and improve drug delivery to reduce side effects and increase therapeutic effectiveness.
The synthesis of LOCs typically involves chemical conjugation methods, such as using cross-linking agents or chemical modifications. The process ensures that the lipid and oligonucleotide are covalently bonded, resulting in a stable conjugate with desired properties.
In gene therapy, LOCs improve gene stability and controlled release, which helps prevent degradation and enhances the delivery of therapeutic genes into cells. This leads to more effective gene therapies with fewer side effects.
Common lipids used in LOCs include phospholipids, cholesterol, and fatty acids. These lipids are selected based on their ability to stabilize the conjugates and ensure effective delivery to targeted cells.
Purity is ensured through rigorous purification methods, including high-performance liquid chromatography (HPLC), mass spectrometry (MS), and gel electrophoresis (PAGE). These methods allow BOC Sciences to deliver high-quality conjugates with minimal impurities.
Loading ......
